期刊
OPEN FORUM INFECTIOUS DISEASES
卷 7, 期 4, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofaa130
关键词
chloroquine; clinical trials; coronavirus; COVID-19; Hydroxychloroquine; SARS-CoV-2
资金
- Doris Duke Charitable Foundation
- National Institute of Mental Health [K23MH121220]
- Fogarty International Center [D43TW009345]
- National Institute of Allergy and Infectious Disease [K08AI134262, K23AI138851, T32AI055433]
- Fonds de recherche du Quebec -Sante
- Fundacio Lluita Contra la Sida i les Malalties Infeccioses
- Departament de Salut de la Generalitat de Catalunya
- Juan Rodes Contract of the Instituto de Salud Carlos III, Ministry of Science, Innovation and Universities, Spanish Government [JR19/00002]
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据